The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

• Published in: Oxidative medicine and cellular longevity 2020, Vol.2020 (2020), p.1-13
• Main Authors: Hosseini, Saeed, Ahmaripour, Najva, Mishani, Mahshid Abd, Hedayati, Mehdi, Qorbani, Mostafa, Djafarian, Kurosh, Nasli-Esfahani, Ensieh, Baziar, Nima, Faghfoori, Zeinab
• Format: Article
• Language: English
• Subjects: Adult; Angina pectoris; Antioxidants; Apolipoprotein A-I - drug effects; Apolipoprotein B-100 - drug effects; Atherosclerosis; Cardiovascular disease; Clinical Study; Clinical trials; Diabetes; Dietary Supplements - analysis; Double-Blind Method; Double-blind studies; Enzymes; Gene expression; Humans; Lipoproteins; Lipoproteins, HDL - drug effects; Metabolism; Middle Aged; Oxidative stress; Pathogenesis; Studies; Thioctic Acid - pharmacology; Thioctic Acid - therapeutic use
• ISSN: 1942-0900; 1942-0994
• DOI: 10.1155/2020/5850865

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a new specific vascular inflammation biomarker that is carried by the lipoproteins in the blood and plays a prominent role in the pathogenesis of atherosclerosis. Increased Lp-PLA2 levels and impaired Lp-PLA2 distribution across high-density lipoprotein (HDL) and non-HDL lipoproteins have been reported in diabetic patients, which is associated with the increase in cardiovascular disease (CVD) risk. This study is aimed at investigating the effect of alpha lipoic acid (ALA), as an antioxidant with potential cardioprotective properties, on the Lp-PLA2 mass and its distribution in diabetic patients. In a double-blind, randomized, placebo-controlled clinical trial, seventy diabetic patients were randomly allocated to ALA (1200 mg ALA as two 600 mg capsules/day) and placebo (two maltodextrin capsules/day) groups. The serum levels of total Lp-PLA2 mass, HDL-Lp-PLA2, oxidized low-density lipoproteins (ox-LDL), apolipoprotein A1 (apo A1), lipid profiles, fasting blood sugar (FBS), and insulin were measured, and apolipoprotein B- (apoB-) associated Lp-PLA2 and homeostasis model of assessment index (HOMA-IR) were calculated at the baseline and after 8 weeks of intervention. ALA significantly decreased the ox-LDL, total Lp-PLA2 mass, apoB-associated Lp-PLA2, and percent of apoB-associated Lp-PLA2 and triglyceride and increased the percent of HDL-Lp-PLA2 compared with the placebo group but had no significant effect on HDL-Lp-PLA2 mass, apo A1, lipid profiles, and glycemic indices. There was a positive correlation between the reduction in the ox-LDL level and total Lp-PLA2 mass in the ALA group. In conclusion, ALA may decrease the CVD risk by reducing the ox-LDL and Lp-PLA2 mass and improving the Lp-PLA2 distribution among lipoproteins in type 2 diabetic patients.